title: Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents.
abstract: A novel series of hydrazones were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK has been identified as one of the most highly connected 'hub proteins' in MRSA. PK has been shown to be critical for bacterial survival which makes it a potential target for development of novel antibiotics and the high degree of connectivity implies it should be very sensitive to mutations and thus less able to develop resistance. PK is not unique to bacteria and thus a critical requirement for such a PK inhibitor would be that it does not inhibit the homologous human enzyme(s) at therapeutic concentrations. Several MRSA PK inhibitors (including 8d) were identified using in silico screening combined with enzyme assays and were found to be selective for bacterial enzyme compared to four human PK isoforms (M1, M2, R and L). However these lead compounds did not show significant inhibitory activity for MRSA growth presumably due to poor bacterial cell penetration. Structure-activity relationship (SAR) studies were carried out on 8d and led us to discover more potent compounds with enzyme inhibiting activities in the low nanomolar range and some were found to effectively inhibit bacteria growth in culture with minimum inhibitory concentrations (MIC) as low as 1 μg/mL. These inhibitors bind in two elongated flat clefts found at the minor interfaces in the homo-tetrameric enzyme complex and the observed SAR is in keeping with the size and electronic constraints of these binding sites. Access to the corresponding sites in the human enzyme is blocked.
authors.affiliation: Department of Chemistry, Simon Fraser University, Burnaby, Canada.
authors.forename: Nag S
authors.initials: NS
authors.lastname: Kumar
authors.forename: Emily A
authors.initials: EA
authors.lastname: Amandoron
authors.forename: Artem
authors.initials: A
authors.lastname: Cherkasov
authors.forename: B Brett
authors.initials: BB
authors.lastname: Finlay
authors.forename: Huansheng
authors.initials: H
authors.lastname: Gong
authors.forename: Linda
authors.initials: L
authors.lastname: Jackson
authors.forename: Sukhbir
authors.initials: S
authors.lastname: Kaur
authors.forename: Tian
authors.initials: T
authors.lastname: Lian
authors.forename: Anne
authors.initials: A
authors.lastname: Moreau
authors.forename: Christophe
authors.initials: C
authors.lastname: Labrière
authors.forename: Neil E
authors.initials: NE
authors.lastname: Reiner
authors.forename: Raymond H
authors.initials: RH
authors.lastname: See
authors.forename: Natalie C
authors.initials: NC
authors.lastname: Strynadka
authors.forename: Lisa
authors.initials: L
authors.lastname: Thorson
authors.forename: Edwin W Y
authors.initials: EW
authors.lastname: Wong
authors.forename: Liam
authors.initials: L
authors.lastname: Worrall
authors.forename: Roya
authors.initials: R
authors.lastname: Zoraghi
authors.forename: Robert N
authors.initials: RN
authors.lastname: Young
mesh_terms: D000890:Anti-Infective Agents / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000201:enzymology*; D008958:Models, Molecular; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D011770:Pyruvate Kinase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D000890:Anti-Infective Agents; D047428:Protein Kinase Inhibitors; D011770:Pyruvate Kinase